Incannex Healthcare Inc.
IXHL evidence brief
What we can confirm
- BioSniper Score:
- 7.2 / 10
- Market Cap:
- $39.8M
- Lead Asset:
- ihl-42x (Phase 2)
What it means
What to watch
Prepared research question
What matters most for IXHL—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · IXHL
Incannex Healthcare Inc. is a clinical-stage biopharmaceutical company developing combination therapies, with its lead candidate IHL-42X in Phase 2 for obstructive sleep apnea and a cash position of $67.7M as of 2026-06-30 [sec].
Key risk: Clinical trial failure risk
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$39.8M
Cash Runway
—
Lead Asset
ihl-42x (Phase 2)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 3 clinical trials for Incannex Healthcare Inc..
Incannex Healthcare Inc. is a clinical-stage biopharmaceutical company developing combination therapies, with its lead candidate IHL-42X in Phase 2 for obstructive sleep apnea and a cash position of $67.7M as of 2026-06-30 [sec].
- Lead candidate IHL-42X is in a Phase 2 dose-optimization study (DReAMzz) for obstructive sleep apnea, with first patient dosed in August 2026 [news · 2026-08-25].
- Positive Phase 2 RePOSA results showed AHI reductions of up to 83%, and IHL-42X has received FDA Fast Track designation [news · 2026-08-25].
- Cash and equivalents of $67.7M as of 2026-06-30, with no debt, providing runway for at least 12 months of planned operations [sec] [news · 2026-10-01].
- A U.S. composition and methods patent for IHL-42X has been granted with baseline expiry in 2040 [news · 2026-09-09].
- The company also has a Phase 2 trial for IHL-675A in rheumatoid arthritis and plans to advance PSX-001 to the next clinical phase [catalyst] [news · 2026-01-14].
What works
- Strong cash position of $67.7M as of 2026-06-30 with no debt, providing financial stability for ongoing trials [sec] [news · 2026-10-01].
- IHL-42X has shown positive Phase 2 data (up to 83% AHI reduction) and FDA Fast Track designation, supporting a streamlined development path [news · 2026-08-25].
- Granted U.S. patent for IHL-42X with baseline expiry in 2040 offers long-term intellectual property protection [news · 2026-09-09].
- Non-dilutive capital of more than A$11.2 million received during 2026, reducing shareholder dilution [news · 2026-09-09].
What to weigh
- IHL-42X is still in Phase 2; clinical and regulatory risks remain before potential approval [news · 2026-08-25].
- The company is clinical-stage with no approved products, meaning no revenue from product sales [news · 2026-01-14].
- Dependence on a single lead candidate (IHL-42X) for near-term value creation, with other programs in earlier stages [news · 2026-01-14].
From the filings
Quoted directly from source documents.
IHL-42X Phase 2 DReAMzz study has commenced patient dosing
“Patient dosing commenced in the DReAMzz Phase 2 dose-optimization study of IHL-42X in obstructive sleep apnea”
News · September 9, 2026
Cash position of approximately $70 million with no debt
“Approximately $70 million in cash and no debt, including more than A$11.2 million in non-dilutive capital received during 2026”
News · September 9, 2026
Positive Phase 2 RePOSA results with up to 83% AHI reduction
“positive Phase 2 RePOSA results demonstrating reductions in AHI of up to 83% and FDA Fast Track designation”
News · August 25, 2026
U.S. patent granted for IHL-42X with baseline expiry in 2040
“U.S. composition and methods of treatment patent granted covering IHL-42X with baseline expiry in 2040”
News · September 9, 2026
Catalyst timeline
- 2023-11-22 · Phase 2 start for IHL-675A in rheumatoid arthritis — A Phase II trial evaluating safety and effect on pain and function in rheumatoid arthritis patients.
- 2024-05-02 · Phase 2/3 start for IHL-42X in obstructive sleep apnea — A Phase II/III trial in subjects intolerant, non-compliant, or naïve to positive airway pressure.
- 2026-07-21 · Phase 2 start for IHL-42X DReAMzz study — A Phase II dose-optimization crossover trial in obstructive sleep apnea patients.
Risks & what to watch (4)›
Key risks
- Clinical trial failure risk — IHL-42X is in Phase 2; negative results could halt development and impact valuation [news · 2026-08-25].
- No approved products or revenue — Company has no marketed products, relying on financing for operations; cash burn continues [news · 2026-01-14].
- Single lead candidate dependency — IHL-42X is the primary value driver; setbacks would significantly affect the company [news · 2026-01-14].
- Regulatory and competitive hurdles — OSA market has established therapies; FDA Fast Track does not guarantee approval [news · 2026-08-25].
What to watch
- Top-line data from the DReAMzz Phase 2 study of IHL-42X, expected to read out in 2027 [news · 2026-10-01].
- Progress of the Phase 2 trial for IHL-675A in rheumatoid arthritis, which started in November 2023 [catalyst].
- Advancement of PSX-001 to the next clinical phase, as indicated in the 2026 outlook [news · 2026-01-14].
- Cash runway updates; current $67.7M provides at least 12 months of operations [sec] [news · 2026-10-01].
Sources: Catalysts · News · Generated October 2, 2026 · How we verify sources →
Run Incannex Healthcare Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Incannex Healthcare Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.08
Lead: Phase 2
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
20
Total value held
$3.8M
| Holder | Shares | Value |
|---|---|---|
| polar asset management partners inc. | 625,000 | $1.9M |
| ghisallo capital management llc | 162,855 | $489K |
| mirae asset global etfs holdings ltd. | 149,857 | $450K |
| murchinson ltd. | 104,113 | $312K |
| arete wealth advisors, llc | 73,167 | $220K |
| lpl financial llc | 71,178 | $214K |
| ubs group ag | 40,369 | $121K |
| advisorshares investments llc | 24,503 | $74K |
| commonwealth equity services, llc | 12,112 | $36K |
| osaic holdings, inc. | 6,376 | $19K |
Showing top 10 of 20 institutional holders of Incannex Healthcare Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 20, 2026- % of float
- 5.9%
- Days to cover
- 1.1
- Shares short
- 814,576
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
IXHL short interestGovernance
Frequently asked questions
What is the AI investment thesis for Incannex Healthcare Inc.?
Incannex Healthcare Inc. is a clinical-stage biopharmaceutical company developing combination therapies, with its lead candidate IHL-42X in Phase 2 for obstructive sleep apnea and a cash position of $67.7M as of 2026-06-30 [sec].
What is Incannex Healthcare Inc.'s lead drug candidate?
Incannex Healthcare Inc.'s most advanced tracked candidate is ihl-42x (Phase 2) for Obstructive Sleep Apnea.
Who is the CEO of Incannex Healthcare Inc.?
Mr. Joel Bradley Latham is the chief executive officer of Incannex Healthcare Inc. (IXHL).
Where is Incannex Healthcare Inc. headquartered?
Incannex Healthcare Inc. (IXHL) is headquartered in Sydney, NSW, Australia.
What therapeutic areas does Incannex Healthcare Inc. focus on?
Incannex Healthcare Inc. develops therapies across Neurology, Immunology, Respiratory, Pain, Musculoskeletal, Psychiatry.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.